Smoking cessation for patients with chronic obstructive pulmonary disease (copd): An evidence-based analysis

Ontario Health Technology Assessment Series

Volumn 12, Issue 4, 2012, Pages 1-50

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; NICOTINE PATCH; NICOTINIC AGENT; NORTRIPTYLINE; PLACEBO; VARENICLINE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMITTENT POSITIVE PRESSURE VENTILATION; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; OXYGEN SATURATION; OXYGEN THERAPY; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING CESSATION; SPIROMETRY; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; REVIEW;

COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84871324345     PISSN: 19157398     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006 Nov;61(11):935-9.
2. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 Feb 22;356(8):775-89.
3. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008 Jan 1;177(1):19-26.
4. Hughes JR. Motivating and helping smokers to stop smoking. J Gen Intern Med. 2003 Dec;18(12):1053-7.
5. Vozoris NT, Stanbrook MB. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. Respir Med. 2010 Sep 15.
6. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010 Aug;65(8):711-8.
7. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004 Jun 19;328(7454):1490.
8. Goodman, C. Literature searching and evidence interpretation for assessing health care practices. Stockholm, Sweden: Swedish Council on Technology Assessment in Health Care; 1996 81 p. SBU Report No. 119E.
9. van der Meer RM WEORJAvSOP. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD002999. DOI: 10.1002/14651858.CD002999.
10. Wagena EJ, van der Meer RM, Ostelo RJWG, Jacobs JE, Van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: Results from a systematic review. Respir Med. 2004;98(9):805-15.
11. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009 Sep;34(3):634-40.
12. Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology (Berl). 1995 May;119(2):193-204.
13. Brandt CJ, Ellegaard H, Joensen M, Kallan FV, Sorknaes AD, Tougaard L, et al. Effect of diagnosis of 'smoker's lung'. Lancet. 1997;349(9047):253.
14. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233-9.
15. Tashkin DP, Murray RP. Smoking cessation in chronic obstructive pulmonary disease. Respir Med. 2009 Jul;103(7):963-74.
16. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest. 2006 Aug;130(2):334-42.
17. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497-505.
18. Pederson LL, Wanklin JM, Lefcoe NM. The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. Int J Addict. 1991 Jan;26(1):107-19.
19. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001 May 19;357(9268):1571-5.
20. Murray RP, Anthonisen NR, Connett JE, Wise RA, Lindgren PG, Greene PG, et al. Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. J Clin Epidemiol. 1998;51(12):1317-26.
21. Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, Van Schayck CP. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005 Oct 24;165(19):2286-92.
22. Sundblad BM, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res. 2008 May;10(5):883-90.
23. Kotz D, Wesseling G, Huibers MJ, van Schayck OC. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J. 2009 Apr;33(4):754-62.
24. Sundblad BM, Larsson K, Nathell L. Low awareness of COPD among physicians. Clin Respir J. 2008 Jan;2(1):11-6.
25. Hilberink SR, Jacobs JE, Breteler M, de Vries H, Grol R. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: Impact after 1 year of two complex interventions [Internet]. [updated 2010; cited 2010 Apr 1]. Available from: www.elsevier.com/locate/pateducou
26. Hilberink SR, Jacobs JE, Bottema BJ, de VH, Grol RP. Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Prev Med. 2005 Nov;41(5-6):822-7.
27. Wilson JS, Fitzsimons D, Bradbury I, Stuart EJ. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. Int J Nurs Stud. 2008 Apr;45(4):508-17.
28. Sundblad BM, Larsson K, Nathell L. Lung function testing influences the attitude toward smoking cessation. Nicotine Tob Res. 2010 Jan;12(1):37-42.
29. Kotz D, van de KK, Jobsis Q, Van Schayck CP. Effects of tobacco exposure on lung health and pulmonary biomarkers in young, healthy smokers aged 12-25 years: a systematic review. Expert Rev Respir Med. 2007 Dec;1(3):403-18.
30. Borglykke A, Pisinger C, Jorgensen T, Ibsen H. The effectiveness of smoking cessation groups offered to hospitalised patients with symptoms of exacerbations of chronic obstructive pulmonary disease (COPD). Clin Respir J. 2008 Jul;2(3):158-65.
31. Christenhusz L, Seydel E, Pieterse M, van d, V, van-der PJ. The SMOKE study: 1 year evaluation of an intensive multi-component smoking cessation programme for COPD outpatients [Abstract]. Eur Respir J. 2005;26:Abstract.
32. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995 Aug;8(8):1398-420.